---
title: "Varegacestat (AL102) in Desmoid tumors: Natural history, survival, and mortality"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Natural history, survival, and mortality. Topics: Variable clinical course: growth, stabilization, and regression; Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis; Active surveillance: Italian prospective multicenter observational study, primary sporadic desmoid fibromatosis; Active surveillance: prospective multicenter observational study of primary sporadic tumors of the extremity or abdominal or thoracic wall; 14 further topics. 18 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Variable clinical course: growth, stabilization, and regression

> “According to estimates, approximately 10–28% of DT will resolve spontaneously without treatment (22% for extra-abdominal tumors to 28% for abdominal tumors)”
> “30% will cycle through progression and resolution, 50% will remain stable after diagnosis, and 10% will progress rapidly”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Desmoid tumors exhibit a variable clinical course, but evidence suggests that the initial period of tumor growth is followed by a long period during which the tumor is stable or may even regress.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.3-2"></a>

### Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis

> “Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach.”
> “Patients ( n = 282) with a median follow-up of 53 months (IQR, 39–63) were included.”
> “The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.”
> “The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”
> “This study confirms that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.1.3-3"></a>

### Active surveillance: Italian prospective multicenter observational study, primary sporadic desmoid fibromatosis

> “This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.”
> “From 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm.”
> “At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%].”
> “TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).”

Source: [Colombo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35247923/)

<a id="topic-2.2.1.3-4"></a>

### Active surveillance: prospective multicenter observational study of primary sporadic tumors of the extremity or abdominal or thoracic wall

> “This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.”
> “Between 2012 and 2015, 100 patients were enrolled.”
> “Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%).”
> “Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).”

Source: [Bonvalot et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37777684/)

<a id="topic-2.2.1.3-5"></a>

### Active surveillance at all anatomic locations: United Kingdom sarcoma reference center

> “Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.”
> “The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.”
> “Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.”
> “Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

<a id="topic-2.2.1.3-6"></a>

### Surgery compared with wait-and-see: prospective cohort of 771 cases

> “We conducted a prospective study of 771 confirmed cases of DTF.”
> “Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).”
> “The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations.”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.1.3-7"></a>

### Event-free survival in the ALTITUDES nationwide prospective cohort

> “ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.”
> “We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy.”
> “The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients.”
> “The median follow-up period was 24.7 (range, 0.4-59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%-71.2%].”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

<a id="topic-2.2.1.3-8"></a>

### Spontaneous regression in the placebo group of a prospective trial

> “Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.”
> “Spontaneous regression is reported in up to 20% of patients.”
> “Our prospective trial, in which desmoid tumors in patients who were taking placebo were evaluated, provides evidence in support of an initial period of observation in patients with newly diagnosed desmoid tumors, given that 20% of the patients in the placebo group had disease regression.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.1.3-9"></a>

### Local recurrence after complete gross resection: nomogram cohort of 439 patients

> “Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence.”
> “Five-year local recurrence–free survival (LRFS) was 69%.”
> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin.”
> “Abdominal wall tumors had the best outcome (5-year LRFS 91%).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.1.3-10"></a>

### Local recurrence after surgery: participant-reported data

> “Continued tumor regrowth or recurrence following any DT treatment was reported for 46% (92/202) of participants, with a higher rate post-surgery (63%, 103/163), regardless of tumor location”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.3-11"></a>

### Recurrence by tumor location and familial adenomatous polyposis status

> “Tumors on extremities are believed to be locally aggressive and have recurrence rates ranging from 24% to 77%”
> “Local recurrence rates of intra-abdominal tumors in patients with FAP are higher than those for extra-abdominal tumors and reported to be 57–86%”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Up to ~60-80% of patients experience recurrence, which can be exacerbated by surgery.”
> “The recurrence rate of desmoid tumors is associated with tumor location and underlying genetic mutation. For example, tumors on the extremities have recurrence rates of up to 77% and intra-abdominal tumors recur much more frequently than extra-abdominal tumors in patients with familial adenomatous polyposis.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.3-12"></a>

### Disease duration: company presentation

> “~50% of patients have desmoid tumors for more than 5 years”
> “K Mercier et al.”
> “ESMO Sarcoma 2024 Poster”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.3-13"></a>

### Mortality: desmoid tumors overall

> “While lacking metastatic potential, the natural history of DT is variable and ranges from an asymptomatic, indolent course to aggressive infiltration of neurovascular structures and vital organs resulting in pain, disfigurement, organ dysfunction, and— rarely—death (usually related to complications such as intestinal obstruction associated with progression of intra-abdominal tumors)”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Desmoid tumors (DTs) are rare soft tissue mesenchymal neoplasms that may be associated with impairments, disfigurement, morbidity, and (rarely) mortality.”

Source: [Riedel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9546183/)

> “Desmoid tumors, despite being highly morbid, typically have a limited impact on mortality.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.3-14"></a>

### Mortality after resection: nomogram cohort

> “Eight patients died of disease, all after R2 resection.”
> “Overall, 44 patients were dead at last follow-up, but only 8 died of disease.”
> “Two patients died following intestinal transplant.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.1.3-15"></a>

### Mortality: Danish patients compared with a healthy matched cohort

> “that has reported a 5-year mortality rate of 7 per 1000 [95% confidence interval (CI) 3–16] among Danish patients with DT as compared with 5 per 1000 (95% CI, 4–7) in a healthy matched cohort.”
> “The authors state that most deaths occurred in patients with FAP, though they represented only 7% of patients in the DT cohort.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.3-16"></a>

### Mortality: intra-abdominal desmoid tumors in familial adenomatous polyposis by stage

> “Intra-abdominal desmoid tumors are one of the leading causes of death in patients with familial adenomatous polyposis.”
> “A total of 154 patients with intra-abdominal desmoid tumors were included in the study.”
> “Five-year survival of patients with stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively (P < 0.001). Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages. Five-year survival rate of stage IV patient with all of the above-mentioned risk factors was only 53%.”

Source: [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/)

<a id="topic-2.2.1.3-17"></a>

### Mortality: home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids

> “Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).”
> “The need for HPN represented a strong predictor of mortality (5-year survival HPN = 72% vs non-HPN = 95%), but duration of HPN did not affect mortality.”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.3-18"></a>

### Desmoid disease as a cause of death in familial adenomatous polyposis

> “Desmoid is a major source of mortality in FAP.”

Source: [Zare et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13591399/)

> “Desmoid tumours (DT) are one of the main causes of death in patients with familial adenomatous polyposis (FAP).”

Source: [Aelvoet et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9636104/)

> “Desmoid tumors (DT) are a leading cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP), yet available data on DT risk remain limited and have been largely derived from large registries or tertiary referral centers.”

Source: [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/)

Additional sources: [Salas et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21844500/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
